董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David H. Deming | 男 | Independent Director and Lead Independent Director | 73 | 6.01万美元 | 1.40 | 2026-09-28 |
| Jonathan E. Freeman | 男 | Director | 58 | 8.91万美元 | 1.61 | 2026-09-28 |
| R. Todd Plott | 男 | Director | 64 | 未披露 | 未持股 | 2026-09-28 |
| Patricia A. Bradford | 女 | Director | 75 | 10.05万美元 | 2.72 | 2026-09-28 |
| Robert J. Bitterman | 男 | Chair of the Board and Chief Executive Officer and Director and President | 75 | 115.94万美元 | 30.14 | 2026-09-28 |
| Curtis A. Lockshin | 男 | Director | 65 | 8.63万美元 | 1.86 | 2026-09-28 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Lisa C. Carson | 女 | Chief Financial Officer and Vice President, Finance and Administration | 60 | 37.30万美元 | 4.70 | 2026-09-28 |
| Robert J. Bitterman | 男 | Chair of the Board and Chief Executive Officer and Director and President | 75 | 115.94万美元 | 30.14 | 2026-09-28 |
董事简历
中英对照 | 中文 | 英文- David H. Deming
-
David H. Deming，他一直担任董事（2015年4月以来）。他一直担任TAG Healthcare Advisors公司的管理合伙人（2013年4月以来）。从2012年9月到2013年3月，他曾担任Deming & Co.（医疗咨询公司）的负责人。从2010年6月到2012年8月，他曾任职Dimensional Fund Advisors公司，在那里他曾担任Dimensional SmartNest公司（个人养老金计划的供应商）的首席执行官。从1977年5月到2000年12月，他曾担任J.P. Morgan & Co. Incorporated公司、J.P. Morgan Chase & Co.公司的投资银行家（从2001年1月到2003年2月）。
David H. Deming has served as a member of the Board since February 2025 and currently serves as Phio Pharmaceuticals Corp.'s Lead Independent Director. Mr. Deming currently serves as the President and CEO of Barramundi Capital LLC (formerly Parker Street Securities), a broker dealer for private placements of private securities, a position he has held since April 2023. Mr. Deming has also been a Senior Advisor at ID Fund Advisors LLC, a registered investment adviser, since June 2018. From April 2013 to February 2018, Mr. Deming served as Managing Partner of TAG Healthcare Advisors, where he advised healthcare companies on business and financial strategies. Mr. Deming currently serves on the board of directors of Better For You Wellness, Inc. (OTC: BFYW), where he is a member of the audit committee. Mr. Deming began his career at J.P. Morgan in 1976 and was a Managing Director in charge of the Global Healthcare Investment Banking Group from 1991 to 2003. Mr. Deming received a B.A. in Economics from Hobart College. - David H. Deming，他一直担任董事（2015年4月以来）。他一直担任TAG Healthcare Advisors公司的管理合伙人（2013年4月以来）。从2012年9月到2013年3月，他曾担任Deming & Co.（医疗咨询公司）的负责人。从2010年6月到2012年8月，他曾任职Dimensional Fund Advisors公司，在那里他曾担任Dimensional SmartNest公司（个人养老金计划的供应商）的首席执行官。从1977年5月到2000年12月，他曾担任J.P. Morgan & Co. Incorporated公司、J.P. Morgan Chase & Co.公司的投资银行家（从2001年1月到2003年2月）。
- David H. Deming has served as a member of the Board since February 2025 and currently serves as Phio Pharmaceuticals Corp.'s Lead Independent Director. Mr. Deming currently serves as the President and CEO of Barramundi Capital LLC (formerly Parker Street Securities), a broker dealer for private placements of private securities, a position he has held since April 2023. Mr. Deming has also been a Senior Advisor at ID Fund Advisors LLC, a registered investment adviser, since June 2018. From April 2013 to February 2018, Mr. Deming served as Managing Partner of TAG Healthcare Advisors, where he advised healthcare companies on business and financial strategies. Mr. Deming currently serves on the board of directors of Better For You Wellness, Inc. (OTC: BFYW), where he is a member of the audit committee. Mr. Deming began his career at J.P. Morgan in 1976 and was a Managing Director in charge of the Global Healthcare Investment Banking Group from 1991 to 2003. Mr. Deming received a B.A. in Economics from Hobart College.
- Jonathan E. Freeman
-
Jonathan E. Freeman自2017年起担任董事会成员。弗里曼博士目前担任ARTBIO的首席商务官，ARTBIO是一家临床阶段的私营生物制药公司，为肿瘤学开发放射性配体疗法，他自2026年1月以来一直担任这一职务。此前，弗里曼博士曾于2018年担任Anthos Therapeutics，Inc.的创始人兼首席运营官，直至2025年被诺华收购。从2017年到2018年6月，弗里曼博士担任Vedanta Biosciences的首席商务官，该公司是一家临床阶段公司，致力于开发免疫介导疾病的疗法。在加入Vedanta Biosciences之前，Freeman博士曾于2008年至2016年在领先的科技公司默沙东 KGaA担任战略和投资组合管理高级副总裁以及业务发展和许可主管。Freeman博士获得帝国癌症研究基金（现为CRUK）的分子药理学和药物代谢博士学位、剑桥大学的生物化学硕士学位和一级荣誉学位以及圣路易斯韦伯斯特大学的金融专业MBA学位。
Jonathan E. Freeman has served as a member of the Board since 2017. Dr. Freeman currently serves as the Chief Business Officer of ARTBIO, a clinical stage private biopharmaceutical company developing radio ligand therapies for oncology, a role he has held since January 2026. Previously, Dr. Freeman was founder and COO of Anthos Therapeutics, Inc. from 2018 until its acquisition by Novartis in 2025. From 2017 to June 2018, Dr. Freeman held the position of Chief Business Officer of Vedanta Biosciences, a clinical stage company developing therapies for immune mediated diseases. Prior to his role with Vedanta Biosciences, Dr. Freeman was the Senior Vice President of Strategy and Portfolio Management and Head of Business Development and Licensing at Merck KGaA, a leading science and technology company, from 2008 to 2016. Dr. Freeman received a Ph.D. in Molecular Pharmacology and Drug Metabolism from the Imperial Cancer Research Fund (now CRUK), an M.A. and First Class Honours in Biochemistry from Cambridge University and a MBA with a finance major from Webster University, St. Louis. - Jonathan E. Freeman自2017年起担任董事会成员。弗里曼博士目前担任ARTBIO的首席商务官，ARTBIO是一家临床阶段的私营生物制药公司，为肿瘤学开发放射性配体疗法，他自2026年1月以来一直担任这一职务。此前，弗里曼博士曾于2018年担任Anthos Therapeutics，Inc.的创始人兼首席运营官，直至2025年被诺华收购。从2017年到2018年6月，弗里曼博士担任Vedanta Biosciences的首席商务官，该公司是一家临床阶段公司，致力于开发免疫介导疾病的疗法。在加入Vedanta Biosciences之前，Freeman博士曾于2008年至2016年在领先的科技公司默沙东 KGaA担任战略和投资组合管理高级副总裁以及业务发展和许可主管。Freeman博士获得帝国癌症研究基金（现为CRUK）的分子药理学和药物代谢博士学位、剑桥大学的生物化学硕士学位和一级荣誉学位以及圣路易斯韦伯斯特大学的金融专业MBA学位。
- Jonathan E. Freeman has served as a member of the Board since 2017. Dr. Freeman currently serves as the Chief Business Officer of ARTBIO, a clinical stage private biopharmaceutical company developing radio ligand therapies for oncology, a role he has held since January 2026. Previously, Dr. Freeman was founder and COO of Anthos Therapeutics, Inc. from 2018 until its acquisition by Novartis in 2025. From 2017 to June 2018, Dr. Freeman held the position of Chief Business Officer of Vedanta Biosciences, a clinical stage company developing therapies for immune mediated diseases. Prior to his role with Vedanta Biosciences, Dr. Freeman was the Senior Vice President of Strategy and Portfolio Management and Head of Business Development and Licensing at Merck KGaA, a leading science and technology company, from 2008 to 2016. Dr. Freeman received a Ph.D. in Molecular Pharmacology and Drug Metabolism from the Imperial Cancer Research Fund (now CRUK), an M.A. and First Class Honours in Biochemistry from Cambridge University and a MBA with a finance major from Webster University, St. Louis.
- R. Todd Plott
-
R. Todd Plott自2026年起担任董事会成员。Plott博士目前担任Epiphany Dermatology的首席医疗官和董事会成员，自2017年以来一直担任这些职务。在主显节皮肤科之前，普洛特医生从2011年开始经营自己的私人诊所，直到2017年加入主显节皮肤科。从2016年到2021年，普洛特博士在FDA的皮肤病和眼科药物咨询委员会任职。普洛特博士是一名研究皮肤科医生，花了16年时间开发了几种皮肤科医生开得最多的处方药。普洛特博士最著名的发明是Solodyn，有助于治疗中度至重度痤疮。他因发明Solodyn获得了8项专利。普洛特博士还帮助开发了Ziana Gel、Noritate乳膏、Carac乳膏、Lotrisone乳液、Vanos乳膏、Loprox洗发水和许多其他皮肤疗法。在制药行业工作的这几年里，普洛特博士监测了数万名患者和数百项临床试验。普洛特博士获得了得克萨斯大学的医学博士学位。
R. Todd Plott has served as a member of the Board since 2026. Dr. Plott currently serves as Chief Medical Officer and a member of the Board of Directors of Epiphany Dermatology, roles he has held since 2017. Prior to Eiphany Dermatology, Dr. Plott operated his own private practice from 2011 until joining Epiphany Dermatology in 2017. From 2016 to 2021, Dr. Plott served on the FDA's Dermatologic and Ophthalmic Drug Advisory committee. Dr. Plott was a research dermatologist and spent 16 years developing several of the prescription drugs most widely prescribed by dermatologists. Dr. Plott's most notable invention is Solodyn, which helps treat moderate to severe acne. He was awarded 8 patents for his invention of Solodyn. Dr. Plott also helped develop Ziana Gel, Noritate cream, Carac cream, Lotrisone lotion, Vanos cream, Loprox Shampoo, and many other skin treatments. Throughout his years working in the pharmaceutical industry, Dr. Plott monitored tens of thousands of patients and hundreds of clinical trials. Dr. Plott received a Doctor of Medicine from the University of Texas. - R. Todd Plott自2026年起担任董事会成员。Plott博士目前担任Epiphany Dermatology的首席医疗官和董事会成员，自2017年以来一直担任这些职务。在主显节皮肤科之前，普洛特医生从2011年开始经营自己的私人诊所，直到2017年加入主显节皮肤科。从2016年到2021年，普洛特博士在FDA的皮肤病和眼科药物咨询委员会任职。普洛特博士是一名研究皮肤科医生，花了16年时间开发了几种皮肤科医生开得最多的处方药。普洛特博士最著名的发明是Solodyn，有助于治疗中度至重度痤疮。他因发明Solodyn获得了8项专利。普洛特博士还帮助开发了Ziana Gel、Noritate乳膏、Carac乳膏、Lotrisone乳液、Vanos乳膏、Loprox洗发水和许多其他皮肤疗法。在制药行业工作的这几年里，普洛特博士监测了数万名患者和数百项临床试验。普洛特博士获得了得克萨斯大学的医学博士学位。
- R. Todd Plott has served as a member of the Board since 2026. Dr. Plott currently serves as Chief Medical Officer and a member of the Board of Directors of Epiphany Dermatology, roles he has held since 2017. Prior to Eiphany Dermatology, Dr. Plott operated his own private practice from 2011 until joining Epiphany Dermatology in 2017. From 2016 to 2021, Dr. Plott served on the FDA's Dermatologic and Ophthalmic Drug Advisory committee. Dr. Plott was a research dermatologist and spent 16 years developing several of the prescription drugs most widely prescribed by dermatologists. Dr. Plott's most notable invention is Solodyn, which helps treat moderate to severe acne. He was awarded 8 patents for his invention of Solodyn. Dr. Plott also helped develop Ziana Gel, Noritate cream, Carac cream, Lotrisone lotion, Vanos cream, Loprox Shampoo, and many other skin treatments. Throughout his years working in the pharmaceutical industry, Dr. Plott monitored tens of thousands of patients and hundreds of clinical trials. Dr. Plott received a Doctor of Medicine from the University of Texas.
- Patricia A. Bradford
-
Patricia A. Bradford自2022年起担任董事会成员。Bradford女士曾在全球信息技术解决方案公司Unisys Corporation担任全球人力资源高级副总裁，她在Unisys的总服务时间从1982年到2014年退休。在Unisys任职期间，Bradford女士战略性地领导了该组织多个级别的所有全球人力资源计划和举措，包括人才管理，负责监督42个国家的200 +人力资源团队。布拉德福德女士在Unisys的角色逐渐包括人力资源的所有领域，包括在Unisys欧洲总部的海外任务，在那里她为该地区提供人力资源领导。她还作为Unisys美国养老金投资委员会的成员参加了该委员会，该委员会每季度审查一次投资组合和适当的投资策略。在加入Unisys之前，布拉德福德女士于1977年至1982年受雇于审计、咨询、税务和咨询服务公司德勤。在那里，她负责编制现金流量报告、资产负债表和损益表，并专门从事外籍人士纳税申报工作。自2014年以来，布拉德福德女士一直保持着专注于为管理层推荐的高级管理人员和高潜力员工提供个人辅导的咨询业务。Bradford女士获得了沃尔什学院会计和统计专业的学士学位，是一名注册会计师。
Patricia A. Bradford has served as a member of the Board since 2022. Ms. Bradford served as Senior Vice President Global Human Resources at Unisys Corporation, a global information technology solutions company, where her total service at Unisys spanned from 1982 until her retirement in 2014. In her role at Unisys, Ms. Bradford strategically led all global human resource programs and initiatives, including talent management, at multiple levels of the organization overseeing an HR team of 200+ in 42 countries. Ms. Bradford's roles at Unisys progressively included all areas of human resources, including an overseas assignment at the Unisys European headquarters where she provided human resources leadership to the region. She as well participated as a member of the Unisys US Pension Investment Committee, which reviewed the investment portfolio and appropriate investment strategies quarterly. Prior to Unisys, Ms. Bradford was employed by Deloitte, an audit, consulting, tax, and advisory services firm, from 1977 to 1982. There, she was responsible for preparing cash flow reports, balance sheets and income statements as well as specializing in Expatriate tax returns. Since 2014, Ms. Bradford has maintained a consulting practice focused on individual coaching for senior executives and high potential employees recommended by management. Ms. Bradford received a B.S. degree with an emphasis in accounting and statistics from Walsh College and is a Certified Public Accountant. - Patricia A. Bradford自2022年起担任董事会成员。Bradford女士曾在全球信息技术解决方案公司Unisys Corporation担任全球人力资源高级副总裁，她在Unisys的总服务时间从1982年到2014年退休。在Unisys任职期间，Bradford女士战略性地领导了该组织多个级别的所有全球人力资源计划和举措，包括人才管理，负责监督42个国家的200 +人力资源团队。布拉德福德女士在Unisys的角色逐渐包括人力资源的所有领域，包括在Unisys欧洲总部的海外任务，在那里她为该地区提供人力资源领导。她还作为Unisys美国养老金投资委员会的成员参加了该委员会，该委员会每季度审查一次投资组合和适当的投资策略。在加入Unisys之前，布拉德福德女士于1977年至1982年受雇于审计、咨询、税务和咨询服务公司德勤。在那里，她负责编制现金流量报告、资产负债表和损益表，并专门从事外籍人士纳税申报工作。自2014年以来，布拉德福德女士一直保持着专注于为管理层推荐的高级管理人员和高潜力员工提供个人辅导的咨询业务。Bradford女士获得了沃尔什学院会计和统计专业的学士学位，是一名注册会计师。
- Patricia A. Bradford has served as a member of the Board since 2022. Ms. Bradford served as Senior Vice President Global Human Resources at Unisys Corporation, a global information technology solutions company, where her total service at Unisys spanned from 1982 until her retirement in 2014. In her role at Unisys, Ms. Bradford strategically led all global human resource programs and initiatives, including talent management, at multiple levels of the organization overseeing an HR team of 200+ in 42 countries. Ms. Bradford's roles at Unisys progressively included all areas of human resources, including an overseas assignment at the Unisys European headquarters where she provided human resources leadership to the region. She as well participated as a member of the Unisys US Pension Investment Committee, which reviewed the investment portfolio and appropriate investment strategies quarterly. Prior to Unisys, Ms. Bradford was employed by Deloitte, an audit, consulting, tax, and advisory services firm, from 1977 to 1982. There, she was responsible for preparing cash flow reports, balance sheets and income statements as well as specializing in Expatriate tax returns. Since 2014, Ms. Bradford has maintained a consulting practice focused on individual coaching for senior executives and high potential employees recommended by management. Ms. Bradford received a B.S. degree with an emphasis in accounting and statistics from Walsh College and is a Certified Public Accountant.
- Robert J. Bitterman
-
Robert J. Bitterman，他曾担任公司的临时执行主席（从2022年9月到2023年2月），直到被任命为总裁兼首席执行官。他曾担任Cutanea Life Sciences， Inc.的总裁兼首席执行官，这是一家他于2005年立的私人公司，专注于开发治疗皮肤和皮下组织疾病和病症的创新技术，直到2019年3月被美国Biofrontera， Inc.收购。自离开Cutanea以来，他一直退休，直到2022年9月开始担任公司的临时执行主席。在担任Cutanea Life Sciences， Inc.的职务之前，他还担任Isolagen， Inc.的总裁兼首席执行官，Dermik Laboratories的总裁兼总经理，以及Aventis S.A.的财务和商业能力方面的各种职位。他持有the College of the Holy Cross的经济学学士学位和Boston大学的工商管理硕士学位。他还拥有纽约College of Podiatric Medicine的人文文学博士学位（荣誉学位）。
Robert J. Bitterman has served as a member and the Chair of the Board since 2012 and as Phio Pharmaceuticals Corp.'s President and Chief Executive Officer since February 2023. Mr. Bitterman served as the Interim Executive Chair of the Company from September 2022 to February 2023 until his appointment as President and Chief Executive Officer. Mr. Bitterman served as the President and Chief Executive Officer of Cutanea Life Sciences, Inc., a private company he founded in 2005 that focused on developing innovative technologies to treat diseases and disorders of the skin and subcutaneous tissue, until its acquisition by Biofrontera, Inc., USA in March 2019. Since leaving Cutanea, Mr. Bitterman was retired until commencing the Interim Executive Chair role with the Company in September 2022. Prior to his role at Cutanea Life Sciences, Inc., Mr. Bitterman also held the position of President and Chief Executive Officer of Isolagen, Inc., President and General Manager of Dermik Laboratories and various positions of increasing responsibility in financial and commercial capacities within Aventis S.A. Mr. Bitterman holds an A.B. degree in Economics from The College of the Holy Cross and a Master of Business Administration degree from Boston University. He also holds a Doctor of Humane Letters (Honoris Causa) from the New York College of Podiatric Medicine. - Robert J. Bitterman，他曾担任公司的临时执行主席（从2022年9月到2023年2月），直到被任命为总裁兼首席执行官。他曾担任Cutanea Life Sciences， Inc.的总裁兼首席执行官，这是一家他于2005年立的私人公司，专注于开发治疗皮肤和皮下组织疾病和病症的创新技术，直到2019年3月被美国Biofrontera， Inc.收购。自离开Cutanea以来，他一直退休，直到2022年9月开始担任公司的临时执行主席。在担任Cutanea Life Sciences， Inc.的职务之前，他还担任Isolagen， Inc.的总裁兼首席执行官，Dermik Laboratories的总裁兼总经理，以及Aventis S.A.的财务和商业能力方面的各种职位。他持有the College of the Holy Cross的经济学学士学位和Boston大学的工商管理硕士学位。他还拥有纽约College of Podiatric Medicine的人文文学博士学位（荣誉学位）。
- Robert J. Bitterman has served as a member and the Chair of the Board since 2012 and as Phio Pharmaceuticals Corp.'s President and Chief Executive Officer since February 2023. Mr. Bitterman served as the Interim Executive Chair of the Company from September 2022 to February 2023 until his appointment as President and Chief Executive Officer. Mr. Bitterman served as the President and Chief Executive Officer of Cutanea Life Sciences, Inc., a private company he founded in 2005 that focused on developing innovative technologies to treat diseases and disorders of the skin and subcutaneous tissue, until its acquisition by Biofrontera, Inc., USA in March 2019. Since leaving Cutanea, Mr. Bitterman was retired until commencing the Interim Executive Chair role with the Company in September 2022. Prior to his role at Cutanea Life Sciences, Inc., Mr. Bitterman also held the position of President and Chief Executive Officer of Isolagen, Inc., President and General Manager of Dermik Laboratories and various positions of increasing responsibility in financial and commercial capacities within Aventis S.A. Mr. Bitterman holds an A.B. degree in Economics from The College of the Holy Cross and a Master of Business Administration degree from Boston University. He also holds a Doctor of Humane Letters (Honoris Causa) from the New York College of Podiatric Medicine.
- Curtis A. Lockshin
-
Curtis A. Lockshin，博士，2013年4月18日任董事。2014年3月起，任 Xenetic Biosciences, Inc.研究和运营部副总裁，该公司主要进行生物制药和新型肿瘤治疗开发。2013年5月，他任私营制药公司Guardum Pharmaceuticals, LLC总裁和CEO。2011年10月至2013年2月，任跨国制药和诊疗公司OPKO Health, Inc.研发部副总裁，后任该公司顾问直至2013年12月。2011年3月至2013年12月，他任 ChromaDex, Inc.董事会成员，该公司是一家天然产品公司，业务涉及膳食补充剂、食品饮料、医疗美容。2009年10月至2012年9月，他任发展中的生物制药公司Sorrento Therapeutics, Inc.的董事会成员。2004年4月起他任 Ruth K. Broad Biomedical Research Foundation董事会成员。该基金是由Duke University提供校内外及国际资金资助，用于对Alzheimer症和神经元退化症进行基础研究。2003年起他成为医疗保健、生物科技和安全等领域的私营小企业的独立咨询顾问。2002年8月至2003年3月，他获Beyond Genomics, Inc. （现BG Medicine, Inc.）生物发现研究主管，该公司主要研究基于疾病的生物标记发现和治疗靶点识别。1998年6月至2002年7月，他在开发神经中枢和呼吸障碍等的治疗物公司Sepracor, Inc. （现Sunovion Pharmaceuticals Inc.）担任多职。他获有Massachusetts Institute of Technology生命科学专业学士学位和生物化学专业博士学位。
Curtis A. Lockshin has served as a member of the Board since 2013. Dr. Lockshin is currently an independent consultant. Previously, Dr. Lockshin served as the Chief Scientific Officer of Xenetic Biosciences, Inc., a public biopharmaceutical company focused on the development of novel oncology therapeutics, from January 2017 to May 2024. Prior to this appointment, Dr. Lockshin served as Xenetic Biosciences, Inc.'s Vice President of Research and Operations from March 2014 to January 2017. From July 2016 to December 2016, Dr. Lockshin served as Chief Technical Officer of VBI Vaccines, Inc., a company developing vaccines in infectious disease and immuno oncology. In July 2016, VBI Vaccines, Inc. had merged with SciVac Therapeutics, Inc. and its subsidiary SciVac, Ltd., a commercial stage biologics and vaccine company, where Dr. Lockshin had served as Chief Executive Officer and director since September 2014. Since 2004, Dr. Lockshin has served as a Director of the Ruth K. Broad Biomedical Research Foundation, a Duke University Support Corporation. Since May 2013, Dr. Lockshin has also served as President and Chief Executive Officer of Guardum Pharmaceuticals, LLC, a private pharmaceutical company. Dr. Lockshin holds a S.B. degree in Life Sciences and a Ph.D. in Biological Chemistry from the Massachusetts Institute of Technology. - Curtis A. Lockshin，博士，2013年4月18日任董事。2014年3月起，任 Xenetic Biosciences, Inc.研究和运营部副总裁，该公司主要进行生物制药和新型肿瘤治疗开发。2013年5月，他任私营制药公司Guardum Pharmaceuticals, LLC总裁和CEO。2011年10月至2013年2月，任跨国制药和诊疗公司OPKO Health, Inc.研发部副总裁，后任该公司顾问直至2013年12月。2011年3月至2013年12月，他任 ChromaDex, Inc.董事会成员，该公司是一家天然产品公司，业务涉及膳食补充剂、食品饮料、医疗美容。2009年10月至2012年9月，他任发展中的生物制药公司Sorrento Therapeutics, Inc.的董事会成员。2004年4月起他任 Ruth K. Broad Biomedical Research Foundation董事会成员。该基金是由Duke University提供校内外及国际资金资助，用于对Alzheimer症和神经元退化症进行基础研究。2003年起他成为医疗保健、生物科技和安全等领域的私营小企业的独立咨询顾问。2002年8月至2003年3月，他获Beyond Genomics, Inc. （现BG Medicine, Inc.）生物发现研究主管，该公司主要研究基于疾病的生物标记发现和治疗靶点识别。1998年6月至2002年7月，他在开发神经中枢和呼吸障碍等的治疗物公司Sepracor, Inc. （现Sunovion Pharmaceuticals Inc.）担任多职。他获有Massachusetts Institute of Technology生命科学专业学士学位和生物化学专业博士学位。
- Curtis A. Lockshin has served as a member of the Board since 2013. Dr. Lockshin is currently an independent consultant. Previously, Dr. Lockshin served as the Chief Scientific Officer of Xenetic Biosciences, Inc., a public biopharmaceutical company focused on the development of novel oncology therapeutics, from January 2017 to May 2024. Prior to this appointment, Dr. Lockshin served as Xenetic Biosciences, Inc.'s Vice President of Research and Operations from March 2014 to January 2017. From July 2016 to December 2016, Dr. Lockshin served as Chief Technical Officer of VBI Vaccines, Inc., a company developing vaccines in infectious disease and immuno oncology. In July 2016, VBI Vaccines, Inc. had merged with SciVac Therapeutics, Inc. and its subsidiary SciVac, Ltd., a commercial stage biologics and vaccine company, where Dr. Lockshin had served as Chief Executive Officer and director since September 2014. Since 2004, Dr. Lockshin has served as a Director of the Ruth K. Broad Biomedical Research Foundation, a Duke University Support Corporation. Since May 2013, Dr. Lockshin has also served as President and Chief Executive Officer of Guardum Pharmaceuticals, LLC, a private pharmaceutical company. Dr. Lockshin holds a S.B. degree in Life Sciences and a Ph.D. in Biological Chemistry from the Massachusetts Institute of Technology.
高管简历
中英对照 | 中文 | 英文- Lisa C. Carson
Lisa C. Carson自2025年5月起担任Phio Pharmaceuticals Corp.的财务和行政副总裁，自2026年2月起担任Phio Pharmaceuticals Corp.的首席财务官。在加入公司之前，Carson女士曾于2020年2月至2024年11月在Prelude Therapeutics（纳斯达克股票代码：PRLD）担任副总裁兼财务总监，该公司是一家临床阶段精准肿瘤学公司，开发创新的癌症疗法。在担任这一职务期间，她在指导公司完成首次公开募股、建立上市公司基础设施、实施财务控制和SOX相关流程方面发挥了关键领导作用。Carson女士还曾在TELA Bio Inc.和PhaseBio制药担任关键领导职务，承担起越来越多的职责，负责监督财务运营和战略增长计划。在Tela Bio，她在支持公司向其第一个产品的商业运营过渡、建立商业化所需的金融基础设施以及领导公司财务系统的实施以支持可扩展的增长方面发挥了重要作用。卡森女士获得了西切斯特大学会计学学士学位。
Lisa C. Carson has served as Phio Pharmaceuticals Corp.'s Vice President Finance and Administration since May 2025, and as Phio Pharmaceuticals Corp.'s Chief Financial Officer since February 2026. Prior to joining the Company, Ms. Carson served as Vice President and Controller at Prelude Therapeutics, (NASDAQ: PRLD) a clinical stage precision oncology company developing innovative cancer therapies from February 2020 until November 2024. In this role, she played a key leadership role in guiding the company through its initial public offering, establishing public company infrastructure, and implementing financial controls and SOX related processes. Ms. Carson also held key leadership roles at TELA Bio Inc. and PhaseBio Pharmaceuticals, assuming positions of increasing responsibility with oversight of financial operations and strategic growth initiatives. At Tela Bio, she was instrumental in supporting the company's transition into commercial operations of its first product, building the financial infrastructure required for commercialization, and leading the implementation of the company's financial systems to support scalable growth. Ms. Carson received a B.S. in Accounting from West Chester University.- Lisa C. Carson自2025年5月起担任Phio Pharmaceuticals Corp.的财务和行政副总裁，自2026年2月起担任Phio Pharmaceuticals Corp.的首席财务官。在加入公司之前，Carson女士曾于2020年2月至2024年11月在Prelude Therapeutics（纳斯达克股票代码：PRLD）担任副总裁兼财务总监，该公司是一家临床阶段精准肿瘤学公司，开发创新的癌症疗法。在担任这一职务期间，她在指导公司完成首次公开募股、建立上市公司基础设施、实施财务控制和SOX相关流程方面发挥了关键领导作用。Carson女士还曾在TELA Bio Inc.和PhaseBio制药担任关键领导职务，承担起越来越多的职责，负责监督财务运营和战略增长计划。在Tela Bio，她在支持公司向其第一个产品的商业运营过渡、建立商业化所需的金融基础设施以及领导公司财务系统的实施以支持可扩展的增长方面发挥了重要作用。卡森女士获得了西切斯特大学会计学学士学位。
- Lisa C. Carson has served as Phio Pharmaceuticals Corp.'s Vice President Finance and Administration since May 2025, and as Phio Pharmaceuticals Corp.'s Chief Financial Officer since February 2026. Prior to joining the Company, Ms. Carson served as Vice President and Controller at Prelude Therapeutics, (NASDAQ: PRLD) a clinical stage precision oncology company developing innovative cancer therapies from February 2020 until November 2024. In this role, she played a key leadership role in guiding the company through its initial public offering, establishing public company infrastructure, and implementing financial controls and SOX related processes. Ms. Carson also held key leadership roles at TELA Bio Inc. and PhaseBio Pharmaceuticals, assuming positions of increasing responsibility with oversight of financial operations and strategic growth initiatives. At Tela Bio, she was instrumental in supporting the company's transition into commercial operations of its first product, building the financial infrastructure required for commercialization, and leading the implementation of the company's financial systems to support scalable growth. Ms. Carson received a B.S. in Accounting from West Chester University.
- Robert J. Bitterman
Robert J. Bitterman，他曾担任公司的临时执行主席（从2022年9月到2023年2月），直到被任命为总裁兼首席执行官。他曾担任Cutanea Life Sciences， Inc.的总裁兼首席执行官，这是一家他于2005年创立的私人公司，专注于开发治疗皮肤和皮下组织疾病和病症的创新技术，直到2019年3月被美国Biofrontera， Inc.收购。自离开Cutanea以来，他一直退休，直到2022年9月开始担任公司的临时执行主席。在担任Cutanea Life Sciences， Inc.的职务之前，他还担任Isolagen， Inc.的总裁兼首席执行官，Dermik Laboratories的总裁兼总经理，以及Aventis S.A.的财务和商业能力方面的各种职位。他持有the College of the Holy Cross的经济学学士学位和Boston大学的工商管理硕士学位。他还拥有纽约College of Podiatric Medicine的人文文学博士学位（荣誉学位）。
Robert J. Bitterman has served as a member and the Chair of the Board since 2012 and as Phio Pharmaceuticals Corp.'s President and Chief Executive Officer since February 2023. Mr. Bitterman served as the Interim Executive Chair of the Company from September 2022 to February 2023 until his appointment as President and Chief Executive Officer. Mr. Bitterman served as the President and Chief Executive Officer of Cutanea Life Sciences, Inc., a private company he founded in 2005 that focused on developing innovative technologies to treat diseases and disorders of the skin and subcutaneous tissue, until its acquisition by Biofrontera, Inc., USA in March 2019. Since leaving Cutanea, Mr. Bitterman was retired until commencing the Interim Executive Chair role with the Company in September 2022. Prior to his role at Cutanea Life Sciences, Inc., Mr. Bitterman also held the position of President and Chief Executive Officer of Isolagen, Inc., President and General Manager of Dermik Laboratories and various positions of increasing responsibility in financial and commercial capacities within Aventis S.A. Mr. Bitterman holds an A.B. degree in Economics from The College of the Holy Cross and a Master of Business Administration degree from Boston University. He also holds a Doctor of Humane Letters (Honoris Causa) from the New York College of Podiatric Medicine.- Robert J. Bitterman，他曾担任公司的临时执行主席（从2022年9月到2023年2月），直到被任命为总裁兼首席执行官。他曾担任Cutanea Life Sciences， Inc.的总裁兼首席执行官，这是一家他于2005年创立的私人公司，专注于开发治疗皮肤和皮下组织疾病和病症的创新技术，直到2019年3月被美国Biofrontera， Inc.收购。自离开Cutanea以来，他一直退休，直到2022年9月开始担任公司的临时执行主席。在担任Cutanea Life Sciences， Inc.的职务之前，他还担任Isolagen， Inc.的总裁兼首席执行官，Dermik Laboratories的总裁兼总经理，以及Aventis S.A.的财务和商业能力方面的各种职位。他持有the College of the Holy Cross的经济学学士学位和Boston大学的工商管理硕士学位。他还拥有纽约College of Podiatric Medicine的人文文学博士学位（荣誉学位）。
- Robert J. Bitterman has served as a member and the Chair of the Board since 2012 and as Phio Pharmaceuticals Corp.'s President and Chief Executive Officer since February 2023. Mr. Bitterman served as the Interim Executive Chair of the Company from September 2022 to February 2023 until his appointment as President and Chief Executive Officer. Mr. Bitterman served as the President and Chief Executive Officer of Cutanea Life Sciences, Inc., a private company he founded in 2005 that focused on developing innovative technologies to treat diseases and disorders of the skin and subcutaneous tissue, until its acquisition by Biofrontera, Inc., USA in March 2019. Since leaving Cutanea, Mr. Bitterman was retired until commencing the Interim Executive Chair role with the Company in September 2022. Prior to his role at Cutanea Life Sciences, Inc., Mr. Bitterman also held the position of President and Chief Executive Officer of Isolagen, Inc., President and General Manager of Dermik Laboratories and various positions of increasing responsibility in financial and commercial capacities within Aventis S.A. Mr. Bitterman holds an A.B. degree in Economics from The College of the Holy Cross and a Master of Business Administration degree from Boston University. He also holds a Doctor of Humane Letters (Honoris Causa) from the New York College of Podiatric Medicine.